News >

Markman Reflects on Career, Progress in Gynecologic Cancers

Brandon Scalea
Published: Monday, Oct 29, 2018

Maurie Markman, MD
Maurie Markman, MD
The treatment paradigm of gynecologic malignancies is expanding with approved targeted agents and a greater focus on maintaining quality of life (QoL). According to Maurie Markman, MD, the field is moving in a precision-based medicine direction.

, Markman reflected on practice-changing advances during his career and discussed the future of gynecologic cancer treatment.

OncLive: You received the 2018 Giants of Cancer Care® award in Gynecologic Cancer. What are your thoughts on winning this award?

Markman: Obviously, I have somewhat of a unique perspective on the Giants of Cancer Care® since I had the privilege of being involved with the program from the beginning, both as chair and as a member of the committee. I'm very aware of the extraordinary effort that goes into exactly what it says: peer-nominated, peer-selected, and the awards are really meant to say, "Your peers have looked at you as having an impact in the field and on patients."

Going back to the question, to be nominated and selected is a great honor and I'm deeply humbled. It means an incredible amount to me. It's an honor and privilege to me to help create this program. I really can't say more than it is just an incredibly humbling experience.

What are some of your career milestones that you are particularly proud of?

Milestones are really interesting because when you look back at them, you say, "Oh, that was important." You don't really think about it at the time. Certainly, there are a number of things that I'm proud of in retrospect. One of these is the identification—which to us now is obvious—that not only do patients who previously received platinum-based chemotherapy have a high probability of responding again, but we can look at the duration of that prior response as a prediction factor. I had a lot to do with helping to come up with that clinical definition. I've been very proud of the role I played in developing intraperitoneal therapy and putting drugs in the abdominal cavity. This is mostly cisplatin-based therapy. I also look back on the role I played in paclitaxel, which is still a very important drug in the disease.

The concept of maintenance therapy has also grown during my career, and now it's pretty much the standard of care. Bevacizumab (Avastin) and the 3 [FDA-approved] PARP inhibitors have changed this dramatically. This concept of continuing treatment in a patient who responds is a very useful one. The most important contribution I've had is looking at general strategies to improve the survival of women with gynecologic malignancies, but also maintaining the critical factor of QoL as defined by the patient—not by me or anybody else.

What kind of ongoing research in gynecologic cancers are you excited about?

It couldn't be a more exciting time to be a clinician or a clinical investigator in the area of gynecologic malignancies. This is from the perspective that we are still learning about antiangiogenic agents. Looking at PARP inhibitors, we have 3 approved as maintenance therapy in ovarian cancer. Checkpoint inhibitors will soon play a role in subsets of patients with ovarian cancer, cervical cancer, and perhaps endometrial cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication